瑞美谷兰 其他名稱 MRZ-8456 ATC碼
(6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R )-1-methyl-3,4-dihydro-2(1H )-isoquinolinyl]methanone
CAS号 1309783-00-3 PubChem CID ChemSpider UNII CompTox Dashboard (EPA ) 化学式 C 17 H 15 Br N 4 O 摩尔质量 371.24 g·mol−1 3D模型(JSmol )
C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br
InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
Key:TUYZYSNXXSTKQX-LLVKDONJSA-N
瑞美谷兰 (INN :remeglurant;开发代号:MRZ-8456 )是一种选择性mGlu5 受体拮抗剂 的药物。[ 1] [ 2] [ 3] Merz制药正在开发它用于治疗药物引起的运动障碍 ,但至少自2016年以来尚未有任何开发报道。[ 3]
参见
参考资料
^ World Health Organization . International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109 (PDF) . WHO Drug Information (World Health Organization ). 2013, 27 (2) [2024-03-19 ] . (原始内容存档 (PDF) 于2022-01-20).
^ US 7985753 ,Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V,「Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.」,发行于4 August 2006,指定于Merz Pharmaceuticals GmbH
^ 3.0 3.1 Remeglurant . Adis Insight. Springer Nature Switzerland AG. [2024-03-19 ] . (原始内容存档 于2024-03-19).